IL42787A - Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids - Google Patents
Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acidsInfo
- Publication number
- IL42787A IL42787A IL42787A IL4278773A IL42787A IL 42787 A IL42787 A IL 42787A IL 42787 A IL42787 A IL 42787A IL 4278773 A IL4278773 A IL 4278773A IL 42787 A IL42787 A IL 42787A
- Authority
- IL
- Israel
- Prior art keywords
- parts
- sodium
- composition
- hydroxy
- calcium salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims description 9
- 239000004202 carbamide Substances 0.000 title claims description 9
- 230000015572 biosynthetic process Effects 0.000 title claims description 6
- 238000001243 protein synthesis Methods 0.000 title claims description 5
- 230000014616 translation Effects 0.000 title claims description 5
- 229940061720 alpha hydroxy acid Drugs 0.000 title claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 title claims 2
- 150000001413 amino acids Chemical class 0.000 title description 4
- 230000001629 suppression Effects 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 9
- 239000011734 sodium Substances 0.000 claims 9
- 229910052708 sodium Inorganic materials 0.000 claims 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229960004799 tryptophan Drugs 0.000 claims 3
- RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 150000002994 phenylalanines Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35532673A | 1973-04-30 | 1973-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42787A0 IL42787A0 (en) | 1973-10-25 |
| IL42787A true IL42787A (en) | 1977-05-31 |
Family
ID=23397057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42787A IL42787A (en) | 1973-04-30 | 1973-07-19 | Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS49135966A (enrdf_load_stackoverflow) |
| BE (1) | BE803567A (enrdf_load_stackoverflow) |
| CA (1) | CA1023664A (enrdf_load_stackoverflow) |
| DE (1) | DE2335216A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2226994B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1442154A (enrdf_load_stackoverflow) |
| IL (1) | IL42787A (enrdf_load_stackoverflow) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| DE2530246A1 (de) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
| DE2531299A1 (de) * | 1975-07-12 | 1977-01-13 | Fresenius Chem Pharm Ind | L-amino- und hydroxy- und/oder ketosaeuren enthaltende gemische fuer parenterale oder orale anwendung |
| DE2636828A1 (de) * | 1976-08-16 | 1978-02-23 | Fresenius Chem Pharm Ind | L-amonosaeurengemische fuer die behandlung von leberinsuffizienz sowie die herstellung derartiger gemische |
| US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
| US4752619A (en) * | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
| SE8803143L (sv) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Alternativa energisubstrat |
| DE3943424A1 (de) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Infusions- und injektionsloesung zur intravenoesen verabreichung |
| CN103476275A (zh) * | 2011-04-18 | 2013-12-25 | 雀巢产品技术援助有限公司 | 包含α-羟基异己酸的营养组合物 |
-
1973
- 1973-07-05 GB GB3212173A patent/GB1442154A/en not_active Expired
- 1973-07-11 DE DE19732335216 patent/DE2335216A1/de active Pending
- 1973-07-12 CA CA176,338A patent/CA1023664A/en not_active Expired
- 1973-07-19 IL IL42787A patent/IL42787A/en unknown
- 1973-08-03 FR FR7328498A patent/FR2226994B1/fr not_active Expired
- 1973-08-14 BE BE2052988A patent/BE803567A/xx not_active IP Right Cessation
- 1973-10-11 JP JP48114328A patent/JPS49135966A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU6015373A (en) | 1975-03-13 |
| FR2226994A1 (enrdf_load_stackoverflow) | 1974-11-22 |
| JPS49135966A (enrdf_load_stackoverflow) | 1974-12-27 |
| IL42787A0 (en) | 1973-10-25 |
| GB1442154A (en) | 1976-07-07 |
| DE2335216A1 (de) | 1974-11-21 |
| CA1023664A (en) | 1978-01-03 |
| BE803567A (fr) | 1973-12-03 |
| FR2226994B1 (enrdf_load_stackoverflow) | 1977-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4100161A (en) | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids | |
| US4100160A (en) | Therapeutic compositions comprising alpha-hydroxy analogs of essential amino acids and their administration to humans for promotion of protein synthesis and suppression of urea formation | |
| US6054486A (en) | Use of 9-Deoxy-2',9-α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen e)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease | |
| CA2341601C (fr) | Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement | |
| US5863906A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| EP1062879B1 (en) | Aqueous solution for the parenteral nutrition | |
| EP1696932A1 (en) | Use of treprostinil to improve kidney functions | |
| RU2003136759A (ru) | Пролекарства ингибиторов дипептидилпептидазы iv | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| IL42787A (en) | Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids | |
| IL42726A (en) | Composition for promotion of protein synthesis and suppression of urea formation in the body | |
| FI88581B (fi) | Foerfarande foer framstaellning av en naeringstillsats foer behandling av uremi | |
| Connors et al. | The pharmacology and tumour growth inhibitory activity of 1-aminocyclopentane-1-carboxylic acid and related compounds | |
| AU5812394A (en) | Protein preparation for the prevention and therapy of periodontitis or other bacterial pathologies of the oral cavity | |
| Gershoff et al. | Effect of vitamin B6 and magnesium on renal deposition of calcium oxalate induced by ethylene glycol administration. | |
| EP1419129A4 (en) | USE OF BRANCHED CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | |
| CA2134380C (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| JPH04312527A (ja) | 肝不全および肝臓疾患の治療方法 | |
| DE2712777A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper | |
| Martín Calero et al. | Protective effect of L‐arginine against ibuprofen‐induced gastric injury in rats | |
| KR20070086007A (ko) | 당뇨병의 치료를 위한 의약 조성물 | |
| JPH0374327A (ja) | アルコール代謝促進剤 | |
| KR920006904B1 (ko) | 디메르캅토 숙신산(dmsa)을 활성성분으로 한 약제학적 조성물 | |
| US20070141121A1 (en) | Method of treating kidney disease | |
| JPH02131421A (ja) | 肝障害抑制剤 |